Efficacy Response Duration and Toxicity of Rituximab, Fludarabine, and Cyclophosphamide (RFC) as 1st Line Treatment and Rituximab (R) in Maintenance Treatment in Follicular Non Hodgkin (FNH) Lymphoma

PHASE4CompletedINTERVENTIONAL
Enrollment

75

Participants

Timeline

Start Date

September 30, 2004

Primary Completion Date

July 31, 2007

Study Completion Date

July 31, 2008

Conditions
Non Hodgkin Lymphoma
Interventions
DRUG

Rituximab Fludarabine Cyclophosphamide

"Patients receiving from 4 to 6 cycles of chemotherapy (R F C) each 4 weeks depending on haematological tolerance:~RITUXIMAB(R)375 mg/m2 iv,day 3 C1 and day 1 C2-C6,(total dose 375 mg/m2) FLUDARABINE(F):25 mg/m2 iv, day 1-3,(total dose 75 mg/m2) CICLOPHOSPHAMIDE(C)1000 mg/m2 iv, day 1,(total dose 1000 mg/m2)"

Trial Locations (20)

10003

Hospital San Pedro de Alcántara, Cáceres

11510

Hospital de Puerto Real, Puerto Real

27004

Complejo Hospitalario Xeral_Calde, Lugo

28033

MD Anderson Internacional España, Madrid

28034

Hospital Universitario Ramón y Cajal, Madrid

28040

Fundación Jiménez Díaz, Madrid

Hospital Clínico San Carlos, Madrid

28041

Hospital Universitario 12 de Octubre, Madrid

28046

Hospital Universitario La Paz, Madrid

28805

Hospital Universitario Príncipe de Asturias, Alcalá de Henares

28911

Hospital Severo Ochoa, Leganés

28922

Fundación Hospital Alcorcón, Alcorcón

28935

Hospital de Móstoles, Móstoles

28943

Hospital de Fuenlabrada, Fuenlabrada

37007

Hospital Clínico Universitario de Salamanca, Salamanca

40001

Hospital General de Segovia, Segovia

47010

Hospital Clínico del Río Hortega, Valladolid

06080

Hospital Infanta Cristina, Badajoz

08003

Hospital del Mar, Barcelona

08907

Instituto Catalán de Oncología (ICO), Barcelona

All Listed Sponsors
lead

Asociacion Espanola de Hematologia y Hemoterapia

OTHER

NCT01124526 - Efficacy Response Duration and Toxicity of Rituximab, Fludarabine, and Cyclophosphamide (RFC) as 1st Line Treatment and Rituximab (R) in Maintenance Treatment in Follicular Non Hodgkin (FNH) Lymphoma | Biotech Hunter | Biotech Hunter